Citations

Clear

633 citation(s) found for "Reid, J".

Treatment and outcomes of progression of disease post–CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis
Epstein‐Peterson, Zachary D. , Lionel, Anath C. , Joseph, Ashlee , Drill, Esther , Atallah‐Yunes, Suheil Albert , Brooks, Taylor , Chong, Elise A. , Chong, Emeline R. , Cruz, Jamie Dela , Frank, Matthew J. , Jacobson, Caron A. , Beyar‐Katz, Ofrat , Maddocks, Kami J. , McLoughlin, Daniel E. , Navalekar, Rohin, Ryan, Christine E. , Sauter, Craig S. , Sharma, Samanvaya , Shukla, Navika , Therwhanger, Dylan , Besien, Herman J. van, Varon, Ben , Yamshon, Samuel , Palomba, M. Lia , Kumar, Anita , Brooks, Taylor R , Kamdar, Manali , Karmali, Reem , Matasar, Matthew , McLoughlin, Daniel , Rhodes, Joanna , Riedell, Peter A , Ryan, Christine E , Salles, Gilles A , Sawalha, Yazeed , Sharma, Samanvaya , Shouval, Roni , Therwhanger, Dylan , van Besien, Herman , Varon, Ben , Wang, Yucai , Yamshon, Samuel , Zelenetz, Andrew D , Jain, Preetesh , Kumar, Anita , Chong, Elise A , Joseph, Ashlee , Atallah-Yunes, Albert , Ip, Andrew , Iqbal, Madiha , Kamdar, Manali , Karmali, Reem , Matasar, Matthew J. , Merryman, Reid W. , Muñoz, Javier , Navalekar, Rohini, Rhodes, Joanna , Riedell, Peter A. , Salles, Gilles , Sawalha, Yazeed , Wang, Yucai , Zelenetz, Andrew D. , Jain, Preetesh

Mayo Clinic

Blood Advances | August 5, 2025 | Volume: 9 | Issue: 21 | Pages: 5654-5662

10.1182/bloodadvances.2025016315 | PMID 40763269 Get It

Abstract The treatment patterns and clinical outcomes for patients experiencing progression of disease (POD) following CD19-directed chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) mantle cell lymphoma (MCL) are undefined. We identified all patients who received CD19-directed CAR T-cell therapy for R/R MCL therapy across 15 international centers, and studied those experiencing POD post–CAR T-cell therapy in detail. We extracted clinical/treatment/pathologic variables, and associated these features with survival outcomes. In total, 384 patients received CAR T-cell therapy, and 135 (35%) experienced POD. POD occurred at a median of 6 months following CAR T-cell therapy infusion, and most (64%) patients with POD had complete response as best response to CAR T-cell therapy. Tumor features at POD included blastoid/pleomorphic morphology in 29 of 78 (37%) patients, and TP53 mutation in 21 of 41 (51%) patients. Following POD, 17 patients received no further therapy, 13 underwent local therapy, and 105 received systemic therapy. The most common first-line systemic therapies were chemo(immuno)therapy (22 patients; overall response rate [ORR], 40%), pirtobrutinib (17 patients; ORR, 36%), and bispecific antibodies (13 patients; ORR, 67%). Among patients experiencing POD, the median progression-free survival and overall survival (OS) were 2.5 months and 5.4 months, respectively, from POD. Lack of response to CAR T-cell therapy and short time from CAR T-cell therapy infusion to POD (<3 vs 3-6 vs >6 months), among other factors, were associated with inferior OS after POD. In conclusion, we confirm the challenging prognosis for patients experiencing POD following CD19 CAR T-cell therapy for R/R MCL, and establish a benchmark for future investigations in this patient population.
Long-term effects of 4 years of menopausal hormone therapy on white matter integrity
Faubion, Laura L. , Tosakulwong, Nirobul, Lesnick, Timothy G. , Fought, Angela J. , Kendall‐Thomas, June, Kapoor, Ekta , Fields, Julie A. , Bailey, Kent R. , James, Taryn T. , Løbo, Rogerio A. , Pal, Lubna , Hammers, Dustin B. , Cedars, Marcelle I. , Miller, Virginia M. , Harman, S. Mitchell , Gleason, Carey E. , Kantarci, Kejal , Kantarci, Kejal , Mak, Elijah , Kara, Firat , Tosakulwong, Nirobul, Reid, Robert I. , Schwarz, Christopher G. , Manson, JoAnn E. , Hammers, Dustin B , Brinton, Eliot A. , Malek‐Ahmadi, Michael , Naftolin, Frederick , Santoro, Nanette F. , Dowling, N. Maritza

Mayo Clinic

Menopause | July 22, 2025 | Volume: 32 | Issue: 9 | Pages: 818-828

10.1097/gme.0000000000002562 | PMID 40694740 Get It

Objectives: To assess the long-term effects of 4 years of menopausal hormone therapy (mHT) on the brain’s white matter architecture in women who initiated mHT within 3 years of menopause onset. Methods: The Kronos Early Estrogen Prevention Study (KEEPS) was a multicenter, double-blind, randomized, placebo-controlled 4-year mHT trial with treatment arms of oral conjugated equine estrogens (oCEE), transdermal 17β-estradiol (tE2), and placebo in recently postmenopausal women. KEEPS Continuation was an observational follow-up of KEEPS participants. White matter integrity was evaluated in KEEPS Continuation participants 10 years after KEEPS completion using white matter hyperintensity volume, diffusion magnetic resonance imaging (dMRI) techniques, and cerebral infarcts. Linear regression models were fitted for each brain region to evaluate if there were differences in white matter between KEEPS treatment arms. Results: There was no evidence to suggest the long-term effects of 4 years of mHT on brain white matter in KEEPS Continuation participants [n=266, mean age 67 (58-73)]. No differences in dMRI metrics were found in each of the treatment arms (oCEE n=70; tE2 n=79) when compared to placebo (n=94), following a false discovery rate adjustment for multiple comparisons. There were no statistically significant differences in white matter hyperintensity volume or infarct occurrence when comparing each of the treatment arms to placebo. Conclusions: We found no evidence of the long-term effect of 4-year mHT on white matter integrity when compared to placebo, consistent with emerging evidence of the safety of short-term use of mHT in recently postmenopausal women.
Mucinous cystic neoplasm in men: a comparative study
Dundar, Bilge , Adsay, Volkan , Allende, Daniela , Jenkins, Sarah M. , Pai, Rish K. , Passow, Marie R. , Reid, Michelle D. , Westerhoff, Maria , Zen, Yoh , Graham, Rondell P. , Adsay, N Volkan , Allende, Daniela S , Graham, Rondell P , Reid, Michelle D

Mayo Clinic

Histopathology | July 11, 2025 | Volume: 87 | Issue: 4 | Pages: 548-556

10.1111/his.15511 | PMID 40641220 Get It

AimsMucinous cystic neoplasms (MCN) are defined by the presence of an ovarian‐type stroma (OTS). Once ovarian stroma has become a requirement for the diagnosis of MCNs, studies using this criterion have disclosed that MCNs are seen almost exclusively (97%) in women. The occurrence of MCNs (with ovarian stroma) in men is exceedingly rare and raises questions about the origin of OTS and the role of hormones in tumourigenesis. This study aims to investigate the clinical and histopathological features of pancreatic or hepatic MCNs in men.Methods and resultsWe examined the MCN cases in men and compared them with age‐matched women. We further investigated MCN in premenopausal and postmenopausal women to explore the impact of hormonal status.The stromal cellularity tended to be lower in men as compared to women; however, limited numbers prevented statistical significance. Clinical presentation, tumour location, body mass index and cyst complexity were similar between men and age‐matched women, similarly in pre‐ and postmenopausal woman groups. All MCN cases, regardless of gender or hormonal status, showed OTS with positivity for oestrogen receptor (ER), androgen receptor (AR) and SF‐1 immunostains. Additionally, the presence of AR and ER‐beta in lining epithelial cells, in addition to the stromal cells, raised the probability for a potential role for local hormonal signalling in the pathogenesis of these tumours.ConclusionsMCNs in men had overlapping histopathologic and immunohistochemical profiles with those in women, regardless of menopausal status.
A Year in Review from the American Thoracic Society (ATS) 2025 International Conference
Eggleston, Reid, EGGLESTON, REID

Mayo Clinic

Respiratory The American Medical Journal | July 1, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.33590/respiramj/rhyt2481 Get It

THE American Thoracic Society (ATS) International Conference took place in San Francisco, California, USA, from May 17th–21st, 2025, with over 14,000 attendees from more than 100 countries represented. The conference opened with an address from Kimberly Manning, Grady Hospital, Emory University, Atlanta, Georgia, USA, who is renowned for her contributions to the burgeoning field of narrative medicine. “I think the greatest teachers of all are the patients we have a privilege to care for.” She shared the story of a patient hospitalized for severe pneumonia, who gave a very busy Manning this advice: “One person doing one thing for a person other than themselves goes further than you think.” It was against this backdrop of the impact that pulmonologists and intensivists have on the lives of their patients that ATS commenced. During the conference, several thought-provoking and sometimes practice-changing trials were introduced or reviewed, spanning content ranging from septic shock to lung cancer. Herein, we explore some of the highlights of these discussions.
The contemporary management of prostate cancer
Chakrabarti, Deep , Albertsen, Peter C. , Adkins, Aidan, Kishan, Amar U. , Murthy, Vedang, Parker, Chris, Pathmanathan, Angela, Reid, Alison , Sartor, Oliver, Walz, Jochen , Tree, Alison , Walz, Jochen , Tree, Alison C , As, Nicholas van

Mayo Clinic

CA: A Cancer Journal for Clinicians | June 27, 2025 | Volume: 75 | Issue: 6 | Pages: 552-586

10.3322/caac.70020 | PMID 40572035 Get It

Abstract Prostate cancer is the most common cancer in two thirds of the world, with an expected doubling in both incidence and mortality in the next two decades. No strong environmental associations exist for the development of prostate cancer; therefore, lifestyle measures are unlikely to mitigate this increasing burden. The last three decades have seen rapid developments in the diagnostic and therapeutic landscape of prostate cancer, including multiparametric magnetic resonance imaging, positron emission tomography, robotic surgery, image‐guided hypofractionated and stereotactic radiotherapy, novel anti‐androgens and radioligand therapies. Prostate cancer is unique in that not everyone with a diagnosis needs treatment, and active surveillance is the preferred option for some. This review discusses the contemporary management of all stages of prostate cancer in the light of these modern developments, enabling holistic individualization of treatment, and describes the promise of future research to further improve outcomes.
Plasma NfL and GFAP for predicting VCI and related brain changes in community and clinical cohorts
Raghavan, Sheelakumari , Graff‐Radford, Jonathan , Hofrenning, Ekaterina I. , Fought, Angela J. , Kamykowski, Michael G. , Windham, B. Gwen , Lowe, Val J. , Jack, Clifford R. , Petersen, Ronald , Hofrenning, Ekaterina, Jack, Clifford R , Reid, Robert I. , Algeciras‐Schimnich, Alicia , Knopman, David S. , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | June 26, 2025 | Volume: 21 | Issue: 6 | Pages: No page available

10.1002/alz.70381 | PMID 40566826 Get It

AbstractINTRODUCTIONWe investigated the usefulness of plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) for capturing vascular cognitive impairment (VCI) in the context of amyloidosis.METHODSUsing two independent cohorts (n = 1810), we assessed the relationship of plasma NfL and GFAP with (1) vascular brain indices; (2) diagnostic states using the following definitions: vascular versus not (white matter hyperintensity/total intracranial volume ≥ 1.3%), and cognitively impaired (CI) versus cognitively unimpaired (CU) using Clinical Dementia Rating ([CDR] scale ≥ 0.5); and (3) their upstream predictors using structural equation models (SEMs).RESULTSPlasma NfL and GFAP were associated with vascular brain damage and differed across states (VCI > vascular CU > non‐vascular CI > non‐vascular CU). In a population‐based sample, these biomarkers distinguished vascular CU and VCI from non‐vascular CU groups with greater separation in amyloid negative participants. Pathway analyses showed NfL was primarily influenced by systemic/brain vascular health, whereas amyloid contributed to GFAP variability.DISCUSSIONPlasma biomarkers, particularly NfL, capture vascular brain changes and show promise for VCI identification.Highlights Plasma NfL and glial fibrillary acidic protein (GFAP) were associated with vascular brain indices. Plasma biomarkers differed across diagnostic states (VCI > vascular CU > non‐vascular CI > non‐vascular CU). Plasma markers discriminated vascular from non‐vascular states with greater separation in Aβ− participants. NfL was linked to vascular health, while amyloid influenced GFAP variability in the population‐based sample. Future longitudinal frameworks should consider systemic inflammation markers along with these plasma markers to better understand VCID‐related brain changes and cognitive decline.
92 | EO2463 (EO) PEPTIDE IMMUNOTHERAPY IN COMBINATION WITH LENALIDOMIDE (L) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH FOLLICULAR (FL) AND MARGINAL ZONE LYMPHOMA (MZL)
Wallace, D. S., Smith, Stephen D. , García, Carlos Grande, Marolleau, Jean Pierre, García, C. Bousoño , Rinaudo, Paolo , Chêne, Laurent , Fagerberg, Jan , Friedberg, Jonathan W. , Armand, P., Ansell, Stephen M. , Villasboas, José C. , Bosch, Francesc Xavier , Pinto, Antonio , Merryman, Reid W. , Arcaini, Luca , Gutiérrez, Norma C. , Marolleau, Jean‐Pierre, Till, Brian G. , García, C., Filippi, Rosaria De , Rinaudo, P., Fagerberg, J., Zinzani, Pier Luigi

Mayo Clinic

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70093_92 Get It

Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity
Raghavan, Sheelakumari, Costoya‐Sánchez, Alejandro , Mainta, Ismini , Rodríguez-Fonseca, Omar Darío, Perissinotti, Andrés , Gu, Yuna , Yun, Jihwan, Peretti, Débora Elisa , Aguiar, Pablo , Bischof, Gérard N. , Seo, Sang Won , Villeneuve, Sylvia , O’Brien, John T. , Jagust, William, Frisoni, Giovanni B. , Soleimani‐Meigooni, David N. , Carrillo, Marı́a C., Joie, Renaud La , Rabinovici, Gil D. , Apostolova, Liana G. , Pontecorvo, Michael J. , Johnson, Keith A. , Weiner, Michael W. , Petersen, Ronald C., Jack, Clifford R. , Schöll, Michael , Labonté, Anne , Faubert, Anne‐Marie, Mathieu, Axel, Madjar, Cécile , Carrier, Charles Edouard, Kazazian, Christina, Lepage, Claude, Maillet, David , Michaud, Diane, Couture, Doris, Dea, Doris, Courcot, Blandine, Debacker, Clément , Fontaine, David, Knopman, David S. , Multhaup, Gerhard, Maltais, Jean‐Robert, Breitner, John C.S. , Poirier, Judes, Cheewakriengkrai, Laksanun, Sager, Mark A., Dauar‐Tedeschi, Marina, Rajah, Natasha, Aisen, Paul, Toussaint, Paule‐Joanne , Pierre, Bellec, Kostopoulos, Penelope, Étienne, Pierre , Tariot, Pierre N. , Orban, Pierre , Hoge, Rick, Thomas, Ronald J. , Gauthier, Serge , Craft, Suzanne , Montine, Thomas J. , Nair, Vasavan, Bohbot, Véronique D. , Venugopalan, Vinod, Ituria‐Medina, Yasser, Khachaturian, Zaven S., Teigner, Eduard, Anthal, Elena, Yu, Elsa, Ferdinand, Fabiola, Pogossova, Galina, Mayrand, Ginette, Duclair, Guerda, Gagné, Guylaine, Newbold‐Fox, Holly, Leppert, Illana, Tremblay‐Mercier, Jennifer , Frenette, Joanne, Frappier, Josée, Kat, Justin, Miron, Justin , Wan, Karen, Mahar, Laura, Carmo, Leopoldina, Théroux, Louise, Dufour, Marianne, Lafaille‐Magnan, Marie‐Élyse, Savard, Mélissa, Tuwaig, Miranda, Petkova, Mirela, Rioux, Pierre, Meyer, P.T., El‐Khoury, Rana, Gordon, Renee, Giles, Renuka, Das, Samir, Wang, Seqian, Tabrizi, Shirin , Mathotaarachchi, Sulantha , Dubuc, Sylvie, Lee, Tanya , Beaudry, Thomas, Gervais, Valérie, Pagé, Véronique, Desautels, René, Benbouhoud, Fatiha, Saint‐Fort, Eunice Farah, Verfaillie, Sander C.J. , Farzin, Sarah , Salaciak, Alyssa , Tullo, Stéphanie , Daoust, Leslie‐Ann, Köbe, Theresa , McSweeney, Melissa, Nilsson, Nathalie , Pishnamazi, Morteza, Bedetti, Christophe , Hudon, Louise, Greco, Claudia, Chapleau, Marianne , St‐Onge, Frédéric , Boutin, Sophie , Geddes, Maiya R. , Ducharme, Simon , Jean, Gabriel, Sylvain, Elisabeth, Élie, Marie‐Josee, Leblond‐Baccichet, Gloria, Soucy, Jean‐Paul , Ozlen, Hazal , Bailly, Julie, Mohammediyan, Béry, Chen, Yalin , Remz, Jordana, Rentz, Dorene M., Amariglio, Rebecca E. , Blacker, Deborah , Chhatwal, Jasmeer P. , Dickerson, Brad C., Donovan, Nancy J. , Farrell, Michelle E. , Gómez, Cristina Lois, Marshall, Gad A. , Oaoo, Kate, Price, Julie, Prokopiou, Prokopis C. , Reynolds, Gretchen , Skylar-Scott, Irina A., Vila‐Castelar, Clara , Yang, Hyun‐Sik , Trojanowki, John Q., Green, Robert C, Perrin, Richard J. , Shaw, Leslie M. , Potter, William Z. , Bernard, Marie , Jackson, Jonathan, Masliah, Eliezer , Masterman, Donna, Okonkwo, Ozioma, Ryan, Laurie, Silverberg, Nina, Fleisher, Adam , Fockler, Juliet , Conti, Cat, Jin, Chengshi , Nosheny, Rachel L. , Ashford, Mariam, Flenniken, Derek , Kormos, Adrienne, Montine, Tom, Rafii, Michael, Raman, Rema , Gessert, Devon, Salazar, Jennifer, Zimmerman, Caileigh, Cabrera, Yuliana, Walter, Sarah , Miller, Garrett, Coker, Godfrey, Clanton, Taylor, Hergesheimer, Lindsey, Smith, Stephanie , Adegoke, Olusegun, Mahboubi, Payam, Moore, Shelley, Pizzola, Jeremy, Shaffer, Elizabeth , Harvey, Danielle, Forghanian-Arani, Arvin, Borowski, Bret, Ward, Chad, Gunter, Jeff, Kantarci, Kejal, Thompson, Paul , Jahanshad, Neda , DeCarli, Charles , Knaack, Alexander , Fletcher, Evan, Chen, Stephanie R, Choe, Mark, Crawford, Karen , Yuschkevich, Paul A, Reiman, Eric M. , Mathis, Chet, Landau, Susan , Cairns, Nigel J. , Householder, Erin, Franklin, Erin , Bernhardt, Haley, Taylor‐Reinwald, Lisa, Korecka, Magdalena , Figurski, Michal, Neu, Scott, Nho, Kwangsik, Foroud, Tatiana M., Faber, Kelley , Wilmes, Kristi, Thal, Leon J., Dage, Jeffrey L. , Eloyan, Ani , Hammers, Dustin B. , Kirby, Kala, Kramer, Joel, Legarde, Julien, Murray, Melissa E., Newell, Kathy L. , Taurone, Alexander, Thangarajah, Maryanne, Touroutoglou, Alexandra , Clark, David , Day, Gregory S, Duara, Ranjan , Graff-Radford, Neill R, Grant, Ian , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Steven, Sha, Sharon J. , Carrillo, María C. , O'Brien, John Tiernan , Jack, Clifford R , Schöll, Michael , La Joie, Renaud , Rabinovici, Gil D , Dage, Jeffrey L , Rial, Alexis Moscoso , Heeman, Fiona , Raghavan, Sheelakumari , Essen, Martijn van , Camacho, Valle , Silva‐Rodríguez, Jesús , Ribaldi, Federica , Coomans, Emma M. , Brum, Wagner Scheeren , Grothe, Michel J. , Drzezga, Alexander E. , Malpetti, Maura , Rowe, James B. , Giessen, Elsmarieke van de , Ossenkoppele, Rik , Smith, Ruben , Hansson, Oskar , Garibotto, Valentina , Dickerson, Bradford Clark , LaMontagne, Pamela , Sperling, Reisa Anne , Vemuri, Prashanthi , Tam, Angela , Binette, Alexa Pichet , Dansereau, Christian , Picard, Cynthia , Michaud, Diane, Couture, Doris, Cuello, A. Claudio , Barkun, Alan , Evans, Alan Charles , Tardif, Christine Lucas , Knopman, David S. , Near, Jamie , Leoutsakos, Jeannie‐Marie , Brandt, Jason , Pruessner, Jens C. , Morris, John C. , Collins, D. Louis , Chakravarty, M. Mallar , Eisenberg, Mark Jeffrey , Rajah, Maria Natasha , Rosa-Neto, Pedro , Bellec, Pierre , Thomas, Ronald, Fonov, Vladimir , Vallee, Isabelle, Vogel, Jacob W. , Dadar, Mahsa , Appleby, Melissa , Meyer, Pierre‐François, Gonneaud, Julie , Pascoal, Tharick Ali , Vachon‐Presseau, Étienne , Spreng, R. Nathan , Rentz, Dorene M. , Buckley, Rachel F. , Gagliardi, Geoffroy Pierre , Gatchel, Jennifer R. , Guzmán‐Vélez, Edmarie , Jacobs, Heidi I.L. , Jutten, Roos J. , Pardilla‐Delgado, Enmanuelle , Price, Julie C. , Quiroz, Yakeel T. , Schultz, Aaron P. , Schultz, Stephanie A. , Sepulcre, Jorge , Vannini, Patrizia , Toga, Arthur W. , Beckett, Laurel , Saykin, Andrew J. , Potter, William, Barnes, Lisa L. , Gonzalez, Hector, Ho, Carole , Hsiao, John , Jackson, Jonathan , Veitch, Dallas P. , Neuhaus, John M , Rafii, Michael S. , Jimenez‐Maggiora, Gustavo Adolfo , Donohue, Michael , Arani, Arvin , Schwarz, Christopher G. , Jones, David T. , Kantarci, Kejal , Senjem, Matthew L. , Reid, Robert I. , Fox, Nick C. , Malone, Ian B. , Thomopoulos, Sophia I. , Nir, Talia M. , Tosun, Duygu , Das, Sandhitsu R. , Koeppe, Robert A. , Chen, Kewei , Risacher, Shannon L. , Shen, Li , Nudelman, Kelly , Ghetti, Bernardino , Grinberg, Lea T. , Hammers, Dustin B , Kirby, Kala, Kukull, Walter A. , Murray, Melissa E. , Polsinelli, Angelina J. , Atri, Alireza , Duara, Ranjan , Graff‐Radford, Neill R. , Honig, Lawrence S. , Johnson, Erik C. B. , Masdeu, Joseph C , Musiek, Erik , Salloway, Steve , Turner, Raymond Scott , Wingo, Thomas S , Wolk, S. J. , Womack, Kyle

Mayo Clinic

JAMA | June 16, 2025 | Volume: 334 | Issue: 3 | Pages: 229

10.1001/jama.2025.7817 | PMID 40522652 Get It

Importance Tau positron emission tomography (PET) allows in vivo detection of neurofibrillary tangles, a core neuropathologic feature of Alzheimer disease (AD). Objective To provide estimates of the frequency of tau PET positivity and its associated risk of clinical outcomes. Design, Setting, and Participants Longitudinal study using data pooled from 21 cohorts, comprising a convenience sample of 6514 participants from 13 countries, collected between January 2013 and June 2024. Cognitively unimpaired individuals and patients with a clinical diagnosis of mild cognitive impairment (MCI), AD dementia, or other neurodegenerative disorders were included. Exposures Tau PET with flortaucipir F 18, amyloid-β (Aβ) PET, and clinical examinations. Tau PET scans were visually rated as positive according to a US Food and Drug Administration– and European Medicines Agency–approved method, designed to indicate the presence of advanced neurofibrillary tangle pathology (Braak stages V-VI). Main Outcomes and Measures Frequency of tau PET positivity and absolute risk of clinical progression (eg, progression to MCI or dementia). Results Among the 6514 participants (mean age, 69.5 years; 50.5% female), median follow-up time ranged from 1.5 to 4.0 years. Of 3487 cognitively unimpaired participants, 349 (9.8%) were tau PET positive; the estimated frequency of tau PET positivity was less than 1% in those aged younger than 50 years, and increased from 3% (95% CI, 2%-4%) at 60 years to 19% (95% CI, 16%-24%) at 90 years. Tau PET positivity frequency estimates increased across MCI and AD dementia clinical diagnoses (43% [95% CI, 41%-46%] and 79% [95% CI, 77%-82%] at 75 years, respectively). Most tau PET–positive individuals (92%) were also Aβ PET positive. Cognitively unimpaired participants who were positive for both Aβ PET and tau PET had a higher absolute risk of progression to MCI or dementia over the following 5 years (57% [95% CI, 45%-71%]) compared with both Aβ PET–positive/tau PET–negative (17% [95% CI, 13%-22%]) and Aβ PET–negative/tau PET–negative (6% [95% CI, 5%-8%]) individuals. Among participants with MCI at the time of the tau PET scan, an Aβ PET–positive/tau PET–positive profile was associated with a 5-year absolute risk of progression to dementia of 70% (95% CI, 59%-81%). Conclusions and Relevance In a large convenience sample, a positive tau PET scan occurred at a nonnegligible rate among cognitively unimpaired individuals, and the combination of Aβ PET positivity and tau PET positivity was associated with a high risk of clinical progression in both preclinical and symptomatic stages of AD. These findings underscore the potential of tau PET as a biomarker for staging AD pathology.
471 | LONGITUDINAL scRNA‐seq CASE STUDY IDENTIFIES THREE STABLE AND DISTINCT B‐CELL SUBTYPES IN SERIAL SAMPLES OF A DIFFUSE B‐CELL LYMPHOMA FROM A SINGLE DOG
Treeful, Amy E. , Macchietto, Marissa , Reid, Kelly, Seelig, Davis , Demos-Davies, Kimberly , Büettner, Manuela , Pracht, Sara, Yung, C., Luethcke, R., Ditcovsky, R., Kuzmik, Alana R., Borgatti, A., Henson, Morgan , Feiock, Caitlin, Sarver, A. L., Walker, G., Winter, A., Buettner, M., Burt, L., Penza, V., Adams, R., Vallera, Daniel A. , Henson, M., Modiano, Jaime F. , Naik, S., Sarver, A. L.

Mayo Clinic

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70096_471 Get It

505 | EMERGING EVIDENCE OF MICROBIOTA COMPOSITION LINKED TO ADVERSE EVENTS DURING IMMUNOTHERAPY IN DOGS WITH LYMPHOMA
Treeful, Amy E. , Dietz, Michael, Reid, Kenneth , Büettner, Manuela , Chehadeh, Andrea, Pracht, Sara, Luethcke, R., Yung, C., Demos-Davies, Kimberly , Seelig, Davis , Feiock, Caitlin, Henson, Morgan , Borgatti, Antonella , Shruthi, N, Dietz, M., Reid, K., Buettner, M., Winter, A., Penza, V., Adams, R., Vallera, Daniel A. , Henson, M., Staley, Christopher , Modiano, Jaime F. , Shruthi, N.

Mayo Clinic

Hematological Oncology | June 15, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70096_505 Get It